Author:
Lortholary A.,El Kouri C.,Ramée J. -F.,Morineau N.,Maillet F.,Le Gouill C.,Terzidis-Mallat E.,Pauvreau O.,Cochery T.,Pioud-Martigny R.,Bonnard D.,Mahot P.
Publisher
Computers, Materials and Continua (Tech Science Press)
Reference19 articles.
1. Audran M, Minebois-Villegas A, Lortholary A, et al. (1984) Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia. Rev Rhum Engl Ed 62: 189–196
2. Fatemi S, Singer FR, Rude RK (1992) Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 50: 107–109
3. Harvey HA (1995) The management of hypercalcemia of malignancy. Support Care Cancer 3: 123–129
4. Hiraki A, Bessho A, Ueoka H, et al. (1998) Tumor-induced hypercalcemia (TIH) in lung cancer: elevated serum level of parathyroid hormone-related protein (PTHrP) predicts poor prognosis in lung cancer patients with hypercalcemia. ASCO annual meeting 1776
5. Hu MI, Gucalp R, Insogna KL, et al. (2011) A single-arm multicenter proof-of-concept study of denosumab to treat hypercalcemia of malignancy in patients who are refractory to IV bisphosphonates. J Clin Oncol 29: (suppl; abstr TPS245)